National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov
In English | En español
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

VEGFR-2 inhibitor peptide CT-322
A highly specific, vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist with potential antiangiogenic activity. Derived from human fibronectin, VEGFR-2 inhibitor peptide CT-322 may block the activation of VEGFR-2 by all known activating ligands, thereby inhibiting the growth of new tumor blood vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Angiocept
Code name:CT-322



Previous:vatalanib, VCL-CB01 vaccine, Vectibix, vector-peptide conjugated paclitaxel, Vectrin
Next:VEGFR1-1084 peptide vaccine, VEGFR2-169 peptide vaccine, velafermin, Velban, VELCADE

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov